Literature DB >> 26187874

Treatment of Liver Cancer.

Chun-Yu Liu1, Kuen-Feng Chen2, Pei-Jer Chen3.   

Abstract

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer. Incidence of liver cancer varies geographically and parallels with the geographic prevalence of viral hepatitis. A number of staging systems have been developed, reflecting the heterogeneity of primary liver cancer, regional preferences, and regional variations in resectability or transplant eligibility. Multimodality treatments are available for this heterogeneous malignancy, and there are variations in the management recommendations for liver cancers across specialties and geographic regions. Novel treatment strategies have merged with the advance of new treatment modalities. This work focuses on reviewing the incidence, staging, and treatment of liver cancer.
Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26187874      PMCID： PMC4561392          DOI： 10.1101/cshperspect.a021535

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN： 2157-1422            Impact factor:   6.915


  127 in total

Review 1.  Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

Authors:  Donald Poon; Benjamin O Anderson; Li-Tzong Chen; Koichi Tanaka; Wan Yee Lau; Eric Van Cutsem; Harjit Singh; Wan Cheng Chow; London Lucien Ooi; Pierce Chow; Maung Win Khin; Wen Hsin Koo
Journal:  Lancet Oncol       Date:  2009-11       Impact factor: 41.316

2.  Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.

Authors:  Jianhua Yin; Nan Li; Yifang Han; Jie Xue; Yang Deng; Jie Shi; Weixing Guo; Hongwei Zhang; Hongyang Wang; Shuqun Cheng; Guangwen Cao
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.

Authors:  Chao-Yuan Huang; Chia-Cheng Wei; Kuei-Chiu Chen; Hui-Ju Chen; Ann-Lii Cheng; Kuen-Feng Chen
Journal:  Cancer Lett       Date:  2011-11-13       Impact factor: 8.679

4.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

6.  The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Authors:  Ta-Chiang Liu; Taeho Hwang; Byeong-Ho Park; John Bell; David H Kirn
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

7.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

8.  Living donor liver transplantation for hepatocellular carcinoma.

Authors:  Sung-Gyu Lee; Deok-Bog Moon
Journal:  Recent Results Cancer Res       Date:  2013

Review 9.  Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review.

Authors:  Feng Xie; Xinji Zhang; Hui Li; Tao Zheng; Feng Xu; Rongxi Shen; Long Yan; Jiamei Yang; Jia He
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

Review 10.  Oncolytic virotherapy for advanced liver tumours.

Authors:  Ju-Fang Chang; Pei-Jer Chen; Daniel Y Sze; Tony Reid; David Bartlett; David H Kirn; Ta-Chiang Liu
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
View more
  73 in total

1.  Construction of ceRNA network and identification of two differentially expressed circRNAs in hepatocellular carcinoma by bioinformatic analysis.

Authors:  Hongwei He; Zhong Shen; Qiyun Gu; Rong Xie
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

2.  Curcumin Activates ROS Signaling to Promote Pyroptosis in Hepatocellular Carcinoma HepG2 Cells.

Authors:  Wan-Feng Liang; Yi-Xi Gong; Hai-Feng Li; Fu-Liang Sun; Wei-Long Li; Dong-Qin Chen; Dan-Ping Xie; Chen-Xi Ren; Xiao-Yu Guo; Zi-Yi Wang; Taeho Kwon; Hu-Nan Sun
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  Lactonic sophorolipid-induced apoptosis in human HepG2 cells through the Caspase-3 pathway.

Authors:  Xiao Wang; Na Xu; Qinglin Li; Shengqi Chen; Hui Cheng; Mo Yang; Ting Jiang; Jun Chu; Xiaojing Ma; Dengke Yin
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-13       Impact factor: 4.813

4.  In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.

Authors:  Ziqiang Ding; Dujin Wang; Wei Shi; Xiaomei Yang; Siliang Duan; Fengzhen Mo; Xiaoqiong Hou; Aiqun Liu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2020-10-29

5.  Classification of hepatic cavernous hemangioma or hepatocellular carcinoma using a convolutional neural network model.

Authors:  Yunbao Cao; Jing Yu; Hu Zhang; Jian Xiong; Zhonghua Luo
Journal:  J Gastrointest Oncol       Date:  2022-04

6.  Clinical and prognostic value of CT perfusion imaging parameters in patients with primary liver cancer after therapy.

Authors:  Yiming Li; Yuzhou Li; Yuan Sui; Guangyao Lin; Wenqi Huang; Yinshi Zheng
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

7.  Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Dan Wang; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

8.  LINC00922 promotes the proliferation, migration, invasion and EMT process of liver cancer cells by regulating miR-424-5p/ARK5.

Authors:  Zhiyu Ye; Qikuan He; Qiaona Wang; Yunshou Lin; Kenan Cen; Xiaogang Chen
Journal:  Mol Cell Biochem       Date:  2021-06-07       Impact factor: 3.396

9.  Propofol activates AMPK to inhibit the growth of HepG2 cells in vitro and hepatocarcinogenesis in xenograft mouse tumor models by inducing autophagy.

Authors:  Yixiong Wang; Baozhu Xu; Jianying Zhou; Xianyan Wu
Journal:  J Gastrointest Oncol       Date:  2020-12

10.  Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.

Authors:  Tuo Deng; Jialiang Li; Bangjie He; Bo Chen; Fangting Liu; Ziyan Chen; Jiuyi Zheng; Zhehao Shi; Tan Zhang; Liming Deng; Haitao Yu; Jinhuan Yang; Lijun Wu; Yunfeng Shan; Zhengping Yu; Xiaolei Chen; Yi Wang; Gang Chen
Journal:  Hepatol Int       Date:  2022-01-22       Impact factor: 6.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.